Close Menu

NEW YORK – Columbus, Ohio-based Sermonix Pharmaceuticals said on Wednesday that it is collaborating with Eli Lilly in an upcoming Phase II trial studying Sermonix's lasofoxifene in combination with Lilly's CDK 4 and 6 inhibitor abemaciclib (Verzenio) in estrogen receptor-positive, HER2-negative metastatic breast cancer patients who also harbor an ESR1 mutation.

The trial, which is expected to start enrolling patients in the third quarter of 2020, will evaluate the safety of the combination treatment.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
LGC SeraCare Life Sciences

This webinar features a panel of industry stakeholders in cancer diagnostics, proficiency testing and clinical care who will discuss the promise and challenges of liquid biopsy technologies in disease diagnosis, monitoring, and patient care management.


Illumina’s BaseSpace Sequence Hub (BSSH) supports primary and secondary analysis of massively parallel sequencing data and can be applied to gene panel data that is generated as part of a clinical cancer assay performed in a pathology lab.


Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers.


This webinar will provide an overview of novel proximal and distal sampling methods that have promise to improve patient outcomes from esophageal cancer.